Latest Bone fracture Stories

Ennis & Ennis P.A. Announces Free Nationwide Consultations to Patients Who Have Suffered Fosamax Femur Fractures or Osteonecrosis of the Jaw as FDA Confirms Long-Term Use of Fosamax Weakens Bones (PRWEB) May 12, 2012 According to an FDA review of biphosphonates published on May 9, 2012 in the New England Journal of Medicine, long term use of these drugs, commonly known as Boniva or Fosamax, could lead to weakened bones. In these cases, women suffered Fosamax side effects including...

A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations. The FDA said doctors need to reassess which women are likely to benefit from bisphosphonates such as Fosamax, Actonel and Reclast, given the lack of concrete evidence that taking them over long periods really helps them and the possibility that they can put some...

Foundation Urges Patients Not to Stop Treatment without Talking to their Healthcare Provider; Experts Available for Comment WASHINGTON, May 10, 2012 /PRNewswire-USNewswire/ -- In response to the Perspectives pieces published online today by the New England Journal of Medicine, the National Osteoporosis Foundation (NOF), the nation's leading community health organization dedicated to preventing osteoporosis and broken bones, commends the U.S. Food and Drug Administration (FDA) for its...

WASHINGTON, May 10, 2012 /PRNewswire/ -- In response to today's Perspective pieces published in the New England Journal Of Medicine, the National Bone Health Alliance (NBHA), a public-private partnership bringing together the expertise and resources of its 42 members from the private and non-profit sectors to collectively advance bone health and prevent disease, commends the U.S. Food and Drug Administration (FDA) for continuing to investigate the risks and benefits of long-term...

ASBMR calls for more research to refine recommendations further The Food and Drug Administration (FDA) announced today that physicians should reassess patients with osteoporosis who are being treated with a class of drugs called bisphosphonates after three to five years of therapy to determine whether they should continue treatment. Bisphosphonates are a widely prescribed class of drugs that are proven to be effective in reducing common bone fractures in people with osteoporosis and at...

Journal of Bone and Joint Surgery Hot Topics ROSEMONT, Ill., May 8, 2012 /PRNewswire-USNewswire/ -- Below are highlights of orthopaedic research studies appearing in the May 2, 2012 issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents. Study Quantifies the High Cost of Hand and Wrist Injuries Injuries to the hand and wrist account for a significant number of annual emergency department visits each year in the U.S. and throughout the...

Journal of Bone and Joint Surgery Hot Topics ROSEMONT, Ill., April 20, 2012 /PRNewswire-USNewswire/ -- Below are highlights of orthopaedic research studies appearing in the April 18th issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents. For more information on these full articles, please contact Lauren Pearson Riley at pearson@aaos.org 847-384-4031 or Kayee Ip at ip@aaos.org or 847-384-4035. Study Looks at Orthopaedic Injuries...

Thirty-two previously unidentified genetic regions associated with osteoporosis and fracture have been identified by a large, worldwide consortium of researchers, including Stanford Prevention Research Center chief John Ioannidis, MD, DSc. Variations in the DNA sequences in these regions confer either risk or protection from the bone-weakening disease. Many, but not all, of the regions encode proteins involved in pathways known to involve bone health. The research shows that osteoporosis...

OR AKIVA, Israel, April 3, 2012 /PRNewswire/ -- Expanding Orthopedics Inc. [http://www.xortho.com ] announced today that the United States Patent and Trademark Office (USPTO) has granted a Patent for its novel expandable device for the treatment of Vertebral Compression Fractures, based on the company's expanding platform technology. Dr. Mark Levy, an orthopedic surgeon and Founder of Expanding Orthopedics, explained that "this new device will be a step forward in...

The US Drug Watchdog is saying, "We want to make certain every woman in the United States who used the osteoporosis drug called Fosamax and then suffered an out of the blue femur break gets identified, and we want to make certain they get to the best possible personal injury attorneys, so they get the maximum possible compensation for what they have been through. Most women victims we have spoken with describe the experience as the post painful of their lives." These type of leg...